Blood Cancers Today @Blood_Cancers Twitter profile

Last Seen Profiles

@AtondoBlessing

@juliusbaer

@Just_Lord_Set

@cloverbiite

@XinNai_Xabrine

@AHwal

@pengen_stw

@mmm_0M5

@pengen_stw

@rayiedee

@sickhoondr

@marsha_sherouse

@ManaTwitch

@LB_cos20

@_DannyKnowles

@dol_glinkerm

@paliharit

@Theta_IS

@b1llshutt

@jaharus1goodwin

@hijabjilbab1

@SloanDave2

@DillonLaird

@Ellahd2024

@YourCoachInSF

@ciggsafterbae

@lbols38

@Lemontea_bs

@galery_basah10

@Da12thMan

@anthonyklotz

@aQGHYdkJZ5GHzfq

@interchainNFTs

@8_IT

@DelphineKr41344

@stwmaniax

Blood Cancers Today

@Blood_Cancers

2 years

Neuro-oncologist @michelle_monje , along with @VirusesImmunity and @PutrinoLab , discovered that chemotherapy and COVID-19 infection cause neuro-inflammation in similar ways

Hematologic Oncology News | Blood Cancers Today

Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, featuring exclusive expert interviews.

bloodcancerstoday.com

1

22

55

Blood Cancers Today

@Blood_Cancers

1 year

🌟ICYMI: In this video, @DrStass , who researches T-cell ALL at @pmcancercentre , speaks about what it means to be named an @AACR NextGen Star and the importance of the opportunity for early career investigators🌟 📺: @PMResearch_UHN @UofT @UHN #AACR23

3

2

42

Blood Cancers Today

@Blood_Cancers

11 months

“Graphical abstract” on the current state of AML classification by @sanamloghavi at #SOHO23 @SocietyofHemOnc

0

9

33

Blood Cancers Today

@Blood_Cancers

1 year

June is Acute Myeloid Leukemia Awareness Month. In this new video, @Dr_AmerZeidan of @Yale speaks about what AML Awareness Month means to him as a clinician and a researcher. 📺: #leusm

1

8

33

Blood Cancers Today

@Blood_Cancers

1 year

🔊OUT NOW: This all-new episode of The HemOnc Pulse features @BldCancerDoc of @SarahCannonDocs and host @chadinabhan discussing CAR-T logistics and access, as well as the role of CAR-T amidst the availability of bispecific antibodies. @SocietyofHemOnc

1

10

33

Blood Cancers Today

@Blood_Cancers

1 year

Today marks AML World Awareness Day. In this new video, @sanamloghavi of @MDAndersonNews discusses the importance of AML World Awareness Day, and how clinicians & researchers can educate others about #AML . 📺Watch: #AMLWorldAwarenessDay #KnowAML #leusm

1

12

31

Blood Cancers Today

@Blood_Cancers

1 year

In this feature, @NoopurRajeMD of @MGHCancerCenter and @harvardmed reflects on the mentors who shaped her career, seeing myeloma treatments go from the bench to the bedside, and the importance of personal priorities during a career in academic medicine.

1

7

31

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: June is Acute Myeloid Leukemia Awareness Month. In this video, @Dr_AmerZeidan of @Yale speaks about what AML Awareness Month means to him as a clinician and a researcher. 📺: #leusm

1

5

29

Blood Cancers Today

@Blood_Cancers

1 year

🌟ICYMI: In this video, @CLJonesLab of @pmcancercentre speaks about her research on leukemia, what it means to be named an @AACR NextGen Star, and the importance of mentorship.🌟 📺: @PMResearch_UHN @UHN @UofT

0

5

29

Blood Cancers Today

@Blood_Cancers

1 year

Do you think CAR-T will replace AHSCT in multiple myeloma? @DoctorAKrishnan of @cityofhopeoc and @szusmani of @MSKCancerCenter shared their thoughts on the matter in this Point | Counterpoint feature. @SocietyofHemOnc

Will CAR-T Therapy Replace AHSCT in Multiple Myeloma? | Blood Cancers Today

Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR T-cell therapy will replace AHSCT in multiple myeloma.

bloodcancerstoday.com

2

9

29

Blood Cancers Today

@Blood_Cancers

1 year

🔊OUT NOW: This all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @Dr_AmerZeidan of @yale about the impact of AML classification updates, how patient characteristics inform his approach to treating AML, and more. @SocietyofHemOnc

0

4

29

Blood Cancers Today

@Blood_Cancers

4 months

S. Vincent Rajkumar ( @VincentRK ) of the @MayoClinic recently assumed the role of Chairperson of the @IMFmyeloma Board of Directors! Read more:

3

4

28

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: @NoopurRajeMD of @MGHCancerCenter / @harvardmed reflects on the mentors who shaped her career, seeing myeloma treatments go from the bench to the bedside, and the importance of personal priorities during a career in academic medicine.

0

6

26

Blood Cancers Today

@Blood_Cancers

2 years

Mahalo nui loa to @MazieTsangMD for stopping by Blood Cancers Today to share about her medical career and how her experience @uhmed taught her "to honor patients’ values, perspectives, and cultures.” @SocietyofHemOnc

1

4

27

Blood Cancers Today

@Blood_Cancers

1 year

The #ASCO23 session on hematologic malignancies - leukemia, myelodysplastic syndromes, and allotransplant has kicked off with a presentation by @drclaireroddie of @ucl on top line results of the FELIX study, which evaluated obecabtagene autoleucel in relapsed/refractory B-ALL.

0

6

24

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: What's the role of transplant in newly diagnosed systemic light chain amyloidosis? @SLentzsch of @columbiacancer and @SandyWong02111 of @UCSF shared their thoughts in this Point | Counterpoint debate.

0

8

23

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: @NoopurRajeMD of @MGHCancerCenter / @harvardmed reflects on the mentors who shaped her career, seeing myeloma treatments go from the bench to the bedside, and the importance of personal priorities during a career in academic medicine. 📚:

0

4

23

Blood Cancers Today

@Blood_Cancers

7 months

DDX41 defies current risk stratification for MDS. R525H mutation results in leukemic transformation. Transplant important for high risk DDX41 patients! Congrats @CarmeloGurnari @NicoGagelmann #mdssm #ASH23

0

10

23

Blood Cancers Today

@Blood_Cancers

1 year

Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in patients with newly diagnosed Ph+ ALL, according to results from the phase III PhALLCON trial by Elias Jabbour, MD, of @MDAndersonNews , and colleagues.

Dr. Elias Jabbour Presents Ponatinib Data from Phase III PhALLCON Trial | Blood Cancers Today

Dr. Elias Jabbour presented data on ponatinib from the phase III PhALLCON trial at the ASCO Plenary Series.

bloodcancerstoday.com

2

7

19

Blood Cancers Today

@Blood_Cancers

1 year

Don't miss the new episode of The HemOnc Pulse on July 27 featuring @NitinJainMD discussing venetoclax and combo therapies in #CLL with host @chadinabhan . Subscribe to all of the latest news in heme onc at: @MDAndersonNews @SocietyofHemOnc

1

4

20

Blood Cancers Today

@Blood_Cancers

1 year

In the first video of a new myeloma roundtable series, @szusmani of @MSKCancerCenter ; @YiLinMDPhD of @MayoClinic ; Shambavi Richard, MD of @TischCancer ; and @MeeraMohanMD of @MedicalCollege , weigh in on triplets vs quadruplets in multiple myeloma. 📺

0

4

18

Blood Cancers Today

@Blood_Cancers

7 months

Let's start the Orals #ASH23 in #myeloma with real world analysis on teclistamab by @DimaDanai @ClevelandClinic #mmsm -overall response similar to trial -complete response lower than trial -extramedullary disease and low performance status is bad Congrats! @NicoGagelmann

1

6

19

Blood Cancers Today

@Blood_Cancers

2 years

Venetoclax plus cladribine, idarubicin, cytarabine showed promise in patients with newly diagnosed AML or high-risk MDS, according to a recent study by Patrick Reville, MD, MPH, @patrickreville of @MDAndersonNews , and colleagues. @SocietyofHemOnc

Venetoclax Plus CLIA as Induction Therapy in AML | Blood Cancers Today

Treatment with venetoclax plus CLIA led to encouraging outcomes in young patients with newly diagnosed AML.

bloodcancerstoday.com

0

6

19

Blood Cancers Today

@Blood_Cancers

1 year

Keep an eye out for our next roundtable, which will feature @YiLinMDPhD ; @szusmani ; Shambavi Richard, MD; and @MeeraMohanMD ! #ASCO23

0

3

18

Blood Cancers Today

@Blood_Cancers

11 months

🔊OUT NOW: This all-new episode of The HemOnc Pulse features @mshadman of @fredhutch discussing the most notable data on CLL from the summer conference season and what he sees on the horizon with host @chadinabhan . Listen: @SocietyofHemOnc

0

5

18

Blood Cancers Today

@Blood_Cancers

1 year

Happening now at #ASCO23 : @Dr_AmerZeidan of @Yale is presenting results from the phase III IMerge study, which evaluated imetelstat in certain patients with LR-MDS.

0

2

18

Blood Cancers Today

@Blood_Cancers

11 months

How I treat MPAL by Dr @CanerSaygin at #SOHO23

1

5

18

Blood Cancers Today

@Blood_Cancers

7 months

At #ASH23 , @NicoGagelmann stopped by Blood Cancers Today to talk about CAR-T versus #HSCT for relapsed #multiplemyeloma . 📺 Watch here!

0

2

17

Blood Cancers Today

@Blood_Cancers

1 year

In this new video, @drsangeetmd of @SylvesterCancer / @UMiamiHealth weighs in on the phase III COMMANDS trial data presented by @garciamanero of @MDAndersonNews during #ASCO23 . 📺:

0

3

17

Blood Cancers Today

@Blood_Cancers

1 year

A triplet of decitabine, venetoclax, and ponatinib was well tolerated in patients with CML in myeloid blast phase or Ph+ AML, according to an ongoing phase II study presented by @jayastuMD of @MDAndersonNews during #ASH22 .

Decitabine, Venetoclax, and Ponatinib Show Promise in CML, AML | Blood Cancers Today

The combination of decitabine, venetoclax, and ponatinib was well tolerated in patients with CML in myeloid blast phase or Philadelphia chromosome-positive AML.

bloodcancerstoday.com

1

4

17

Blood Cancers Today

@Blood_Cancers

7 months

Second-year internal medicine resident Mustafa Wasifuddin, MD ( @teeshake ), joined @chadinabhan to discuss his research on racial disparities in #DLBCL at #ASH23 . Watch the full conversation ➡️

0

3

16

Blood Cancers Today

@Blood_Cancers

2 years

Congratulations to our Blood Cancers Today Editorial Board member, Dr. Elias Jabbour, of @MDAndersonNews , for receiving the King Hussein Lifetime Achievement Award for Cancer Research at this year's King Hussein Cancer Research Conference. @KHCFKHCC @SocietyofHemOnc

Amer Zeidan MBBS,MHS ‏عامر زيدان

@Dr_AmerZeidan

2 years

Many congratulations to dr Elias Jabbour @MDAndersonNews for winning the Life Achievement Award for Cancer Research in @KHCFKHCC Annual Cancer Research Awards meeting in Jordan 🇯🇴 @doctorpemm

8

9

142

0

1

16

Blood Cancers Today

@Blood_Cancers

1 year

Looking forward to catching up on podcasts this evening? Check out The HemOnc Pulse, which is hosted by @chadinabhan and has featured guests including @GregNowakowski , @doctorpemm , @BldCancerDoc , @Dr_AmerZeidan , @ASkarbnik , @DrLizBrem , & @sanamloghavi . 🔊

1

5

16

Blood Cancers Today

@Blood_Cancers

1 year

In our latest Get to Know feature, John DiPersio, MD, PhD, of @DiPersioLab / @wustlmed / @sitemancenter , discusses the key events that shaped his career, his lab’s most transformative research, the future of transplant, and more. 📚:

0

3

16

Blood Cancers Today

@Blood_Cancers

1 year

Catching up on all the key hem/onc news from the 2023 @ASCO Annual Meeting? In this video, @drsangeetmd of @SylvesterCancer / @UMiamiHealth weighs in on data from the phase III COMMANDS trial presented by @garciamanero of @MDAndersonNews at #ASCO2023 . 📺

0

3

16

Blood Cancers Today

@Blood_Cancers

1 year

Thank you to @kanagalshamanna of @MDAndersonNews for taking the time to discuss the optical genome mapping platform and its clinical implications for MDS and AML.

Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping | Blood Cancers Today

Rashmi Kanagal-Shamanna, MD, discusses the optical genome mapping platform and the clinical implications the technology will have for MDS and AML.

bloodcancerstoday.com

0

6

15

Blood Cancers Today

@Blood_Cancers

2 years

Blood Cancers Today is the official news publication of @SocietyofHemOnc . Under the leadership of Editor-in-Chief @SagarLonialMD , BCT covers the latest news and research in hematologic malignancies, offering insight from innovators and experts in the hematology/oncology field.

0

4

16

Blood Cancers Today

@Blood_Cancers

10 months

📢COMING SOON: @RahulBanerjeeMD of @UWMedicine & @fredhutch will be taking over @blood_cancers during the @Myeloma_Society 's 2023 Annual Meeting, which kicks off Wednesday in Athens! 📰Stay tuned for all the latest news and key developments from #IMS2023 ! #mmsm #IMS23

1

4

15

Blood Cancers Today

@Blood_Cancers

1 month

⭐ Valeria Santini, MD ( @Santin13Valeria ), of @UNI_FIRENZE , stopped by for an interview at #EHA2024 !

0

2

16

Blood Cancers Today

@Blood_Cancers

8 months

Lenalidomide-associated acute lymphoblastic leukemia was seen in patients with multiple myeloma, but discontinuation alone led to regression of clonal populations. Read more about this study, led by @MarkGeyerMD , of @MSKCancerCenter . 📝

0

7

16

Blood Cancers Today

@Blood_Cancers

1 year

More than one-third of patients with MDS and their caregivers had “concerning levels of depression and/or anxiety,” according to research by Katherine DiNardo, MD, of @DukeMedSchool .

MDS Has Significant Mental Health Impact on Patients, Caregivers | Blood Cancers Today

More than one-third of patients with myelodysplastic syndromes (MDS) and their caregivers had “concerning levels of depression and/or anxiety."

bloodcancerstoday.com

0

6

15

Blood Cancers Today

@Blood_Cancers

2 months

Out now! 🥳 The #MDS panel from #HOPLive24 discusses: ☑️ How to classify and define MDS and CHIP ☑️ How to treat low- and high-risk MDS ☑️ How to approach transplant Check it out! @Ramikomrokji @Dr_AmerZeidan @drsangeetmd @sanamloghavi @chadinabhan

0

6

15

Blood Cancers Today

@Blood_Cancers

6 months

🙌 ICYMI: The @CRTFund Lifetime Achievement Award recognized @JohnPLeonardMD , of @WeillCornell and @NYPhospital , for his research in lymphoma. Read more:

0

15

Blood Cancers Today

@Blood_Cancers

1 year

🔊Looking for a great listen this weekend? Don't miss this episode of The HemOnc Pulse, which features @BldCancerDoc of @SarahCannonDocs discussing CAR-T logistics, access, and other key considerations with host @chadinabhan . @SocietyofHemOnc

0

3

15

Blood Cancers Today

@Blood_Cancers

1 year

In this video interview, @SwethaKamMD of @cityofhope discusses her #ASCO23 presentation on real-world outcomes of brexucabtagene autoleucel in relapsed or refractory MCL with @chadinabhan . 📺:

1

3

15

Blood Cancers Today

@Blood_Cancers

3 months

🥳🎉 Out now: the first podcast episode from #HOPLive24 ! 🎙️ Panelists @Daver_Leukemia , @sanamloghavi , @Ramikomrokji , and @MikkaelSekeres join @chadinabhan to discuss unanswered questions in #AML . 🎧 Listen here!

1

7

15

Blood Cancers Today

@Blood_Cancers

1 year

Thanks to @garciamanero of @MDAndersonNews for stopping by to discuss results from the phase III COMMANDS study with us during #ASCO23 ! Look for the full video interview with Dr. Garcia-Manero here soon!

1

0

15

Blood Cancers Today

@Blood_Cancers

1 year

Is it time for a unified approach to MDS? In this new feature, @JoeKhouryMD ; Daniel Arber, MD; @DavidSteensma ; @UwePlatzbecker ; @drsomedeb ; @Ramikomrokji ; and Robert Hasserjian, MD, weigh in on the WHO and ICC systems and how to move forward. 📚:

0

6

15

Blood Cancers Today

@Blood_Cancers

1 year

In this new video, @Dr_AmerZeidan of @Yale discusses the phase III IMerge data he presented at #ASCO23 , the study's implications, and what he sees as the next steps. 📺:

0

6

15

Blood Cancers Today

@Blood_Cancers

10 months

Can’t want to get started! #IMS23 #MMsm

0

1

15

Blood Cancers Today

@Blood_Cancers

11 months

COMING SOON: @sanamloghavi of @MDAndersonNews takes over @Blood_Cancers next week for a special livestream with @chadinabhan at #SOHO2023 ! Tune in at 3 PM CT Thursday for all the latest news from the Eleventh @SocietyofHemOnc Annual Meeting! #SOHO23 , #leusm , #lymsm , #mmsm

1

5

15

Blood Cancers Today

@Blood_Cancers

1 month

At #ASCO24 , Eric Winer, MD ( @DanaFarber ) was joined by @yasminabaza1 ( @NorthwesternMed ) and @Daver_Leukemia ( @MDAndersonNews ) to discuss treatment strategies for #AML . Check out the first episode of the #leukemia roundtable here! ➡️

0

4

14

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: Will CAR-T will replace AHSCT in multiple myeloma? @DoctorAKrishnan of @cityofhopeoc and @szusmani of @MSKCancerCenter share their thoughts on the topic in this Point | Counterpoint feature. Read more:

0

4

14

Blood Cancers Today

@Blood_Cancers

2 months

🙌 Out now! The first #MPN roundtable from #HOPLive24 😍 Moderator @mpdrc and panelists @doctorpemm , @sanamloghavi , and @myeloidmalig discuss the key diagnostic standards for #myelofibrosis . 📽️

0

5

14

Blood Cancers Today

@Blood_Cancers

3 months

🙌 @sanamloghavi , of @MDAndersonNews , reflects on "The HemOnc Pulse" Live and how it sheds a spotlight on hematopathology! Hear what she has to say, and stay tuned for the live meeting on May 3-4 in Chicago! 📺 #HOPLive24 @chadinabhan

1

5

13

Blood Cancers Today

@Blood_Cancers

7 months

Time for another #ASH23 video insight! In this interview, @CarlynRTanMD , of @MSKCancerCenter , discussed her retrospective study on teclistamab treatment for multiple myeloma. Watch here:

2

6

14

Blood Cancers Today

@Blood_Cancers

1 year

In our latest "Get to Know" feature, @Dr_AmerZeidan of @Yale / @YaleCancer reflects on a patient who shaped his career path, what he sees as the most pressing questions in the field, and the importance of hope. 📚:

1

4

14

Blood Cancers Today

@Blood_Cancers

1 year

A novel early relapse scoring system for patients with MM undergoing AHSCT identified five discrete prognostic groups, according to a study from the chronic malignancies working party of @TheEBMT published by @mbeksac56 of @AnkaraUni and colleagues. 📚:

0

3

14

Blood Cancers Today

@Blood_Cancers

1 month

Hello Madrid!! 👋 We've arrived onsite at #EHA2024 and can't wait to cover this exciting conference. We'll be live tweeting some sessions tomorrow, so stay tuned! Keep an eye out for conference coverage here as well 😊 @EHA_Hematology

0

2

14

Blood Cancers Today

@Blood_Cancers

3 months

@sanamloghavi also discussed #MRD in #AML : "Not all MRD is created equally," she said. "Not all the assays are as sensitive. So, you really have to know what you're using and how to interpret the data in the context of the greater picture."

0

3

14

Blood Cancers Today

@Blood_Cancers

10 months

On the heels of #IMS23 , we're happy to present @szusmani & @TomBmt133 with our prize for the friendliest boxing hype-up photo of all time* 🥊🥊 * Actually a fierce face-off in #MMsm that was our most read story of the year, even before #IMS23 . Read below!

1

4

14

Blood Cancers Today

@Blood_Cancers

1 year

In this video interview, @Rachel_Thijssen of @CancerCenterAms speaks about the session she chaired during the @young_eha Research Meeting at #EHA2023 and the importance of bringing young researchers together at the 2023 @EHA_Hematology Congress! 📺:

0

2

14

Blood Cancers Today

@Blood_Cancers

1 year

In this new video from the myeloma roundtable series, @szusmani of @MSKCancerCenter ; @YiLinMDPhD of @MayoClinic ; Shambavi Richard, MD of @TischCancer ; and @MeeraMohanMD of @MedicalCollege , discuss maintenance therapy strategies for multiple myeloma. 📺:

0

6

12

Blood Cancers Today

@Blood_Cancers

3 months

🌟 The lights are shining on the stars of the #MPN roundtable! More to come from #HOPLive24 😊 @doctorpemm @mpdrc @sanamloghavi @myeloidmalig

0

1

13

Blood Cancers Today

@Blood_Cancers

1 year

In the latest video from the myeloma roundtable series, @szusmani of @MSKCancerCenter ; @YiLinMDPhD of @MayoClinic ; Shambavi Richard, MD of @TischCancer ; and @MeeraMohanMD of @MedicalCollege , discuss FDA-approved BCMA-directed CAR-T options for MM. 📺:

0

3

13

Blood Cancers Today

@Blood_Cancers

7 months

MPN community saw a potential paradigm shift in treating patients with #myelofibrosis Combination of pelabresib+ruxolitinib resulted in high and deep spleen responses and astonishing tolerability #mpnsm @NicoGagelmann #ASH23

0

2

12

Blood Cancers Today

@Blood_Cancers

10 months

What's the latest in MDS and AML? @Ramikomrokji of @MoffittNews and @Daver_Leukemia of @MDAndersonNews stopped by The HemOnc Pulse at #SOHO23 to share their thoughts with @chadinabhan . Don't miss this great discussion! 📺

0

1

13

Blood Cancers Today

@Blood_Cancers

11 months

Thanks to @AjaiChari of @UCSF for stopping by to discuss the recent FDA accelerated approval of talquetamab for relapsed or refractory multiple myeloma. Stay tuned for the full video interview and sign up to get the latest news in your inbox: #mmsm

0

1

13

Blood Cancers Today

@Blood_Cancers

8 months

What are the "ABCs" of multiple myeloma treatment? @Rfonsi1 jumped on The HemOnc Pulse to chat with @chadinabhan about the future of MM treatment, the ongoing debate between CAR-T therapies and bispecifics, and the latest news on bispecifics. 🎧

0

7

12

Blood Cancers Today

@Blood_Cancers

1 year

🔊Looking for a great listen this weekend? Don't miss the latest episode of The HemOnc Pulse, which features @BldCancerDoc of @SarahCannonDocs discussing CAR-T logistics, access, and other key considerations with host @chadinabhan . @SocietyofHemOnc

0

2

13

Blood Cancers Today

@Blood_Cancers

7 months

Another episode of The HemOnc Pulse just dropped! 🤩 This time, @ASkarbnik , of @NovantHealth , joined @chadinabhan to discuss practice-changing research in #DLBCL presented at #ASH23 . 🎧 Listen here:

0

5

13

Blood Cancers Today

@Blood_Cancers

5 months

Recently, @TaylorJ_MD , of @SylvesterCancer , joined BCT to discuss a study on overcoming BTK-Resistant mutations in #CLL . Dr. Taylor and his team developed the BTK degrader NX-2127, which achieved clinical responses in 79% of patients. 📰 Read more!

0

2

13

Blood Cancers Today

@Blood_Cancers

3 months

We had SO much fun in Chicago at #HOPLive24 this weekend! Check out our coverage and stay tuned for: ⭐ Podcast episodes from each session ⭐ Roundtable discussions ⭐ One-on-one interviews @chadinabhan @Dr_AmerZeidan @MdSwoboda @doctorpemm @mpdrc

2

4

13

Blood Cancers Today

@Blood_Cancers

3 months

All smiles here at #HOPLive24 ! 🤩 @chadinabhan @JaneWinterMD @jmikhaelmd @MikkaelSekeres

0

3

13

Blood Cancers Today

@Blood_Cancers

1 year

Looking for a great read over the weekend? In this feature, @LNastoupilMD of @MDAndersonNews reflects on her upbringing in New Mexico, her research on disparities in lymphoma, the importance of representation in practice-changing trials, and more.

0

4

13

Blood Cancers Today

@Blood_Cancers

3 months

It's Day 1 of #HOPLive24 ! 😍 Join the conversation as @mrbishop_UC_BMT , @ASkarbnik , @Daver_Leukemia , @MikkaelSekeres , @jmikhaelmd , and more join @chadinabhan for panels, interviews, and more exciting stuff! ➡️

0

7

13

Blood Cancers Today

@Blood_Cancers

1 year

As Acute Myeloid Leukemia Awareness Month wraps up, don't miss this video featuring @Dr_AmerZeidan of @Yale sharing what AML Awareness Month means to him as a clinician and a researcher. 📺: #leusm

0

1

13

Blood Cancers Today

@Blood_Cancers

7 months

Good morning beautiful hematologists in wonderful San Diego! Stay tuned and excited for today's #ASH23 reports: "Today is gonna be the day that I'm gonna throw myeloma, MDS and CAR-T at you." @NicoGagelmann

0

3

12

Blood Cancers Today

@Blood_Cancers

1 year

Venetoclax plus azacitidine maintenance therapy after allogeneic HSCT showed “encouraging activity” in patients with high-risk MDS or AML, according to a study by Jacqueline Garcia, MD, of @danafarber , and colleagues.

0

2

12

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: Should CAR-T or a bispecific antibody be used to treat relapsed/refractory multiple myeloma? @TomBmt133 of @UCSFCancer and @szusmani of @MSKCancerCenter debate the topic in this Point | Counterpoint feature.

0

3

12

Blood Cancers Today

@Blood_Cancers

3 months

@MDAndersonNews @TheLancetHaem 🙌 If you've been keeping up with our previous Top 5 countdowns, you're probably not surprised that this popular "HemOnc Pulse" episode with @AaronGoodman33 & @chadinabhan takes the #4 spot! 🎧 Listen to the full podcast to learn about Castleman Disease:

1

2

12

Blood Cancers Today

@Blood_Cancers

11 months

Looking for a great listen this weekend? Check out The HemOnc Pulse, which is hosted by @chadinabhan and has featured guests including @tinabhatnagar01 , @NitinJainMD , @SwethaKamMD , @BldCancerDoc , @ASkarbnik , @Dr_AmerZeidan , @graham74GC & @SagarLonialMD .

0

3

12

Blood Cancers Today

@Blood_Cancers

10 months

How does CAR-T impact the standard of care in myeloma? In the second segment of this all-new myeloma roundtable series, hear from @SagarLonialMD of @WinshipAtEmory ; @NoopurRajeMD of @harvardmed , @MGHCancerCenter ; and @DrKrinaPatel of @MDAndersonNews . 📺

0

4

12

Blood Cancers Today

@Blood_Cancers

5 months

"Rare diseases are not rare for the patients or their families that are affected by them." @MrinalPatnaik recognizes #rarediseaseday @MayoClinic #CMML via @YouTube

Dr. Mrinal Patnaik of #mayoclinic #CMML Recognizes #rarediseaseday

Dr. Patnaik of Mayo Clinic recognizes Rare Disease Day.Like and subscribe to @bloodcancerstoday2935 for the latest hematology-oncology news.

www.youtube.com

0

4

11

Blood Cancers Today

@Blood_Cancers

7 months

We have another special #ASH23 episode of The HemOnc Pulse! This time, @drsangeetmd spoke with @chadinabhan about the latest MDS news from ASH—including the investigational drug KER-050, and whether she believes MDS is a distinct disease. 🎧Listen here!

2

4

11

Blood Cancers Today

@Blood_Cancers

1 year

In this new video, BCT Editor-in-Chief @SagarLonialMD of @WinshipAtEmory discusses the symposium he took part in during #EHA23 and key highlights in multiple myeloma research presented during the 2023 @EHA_Hematology Congress and the 2023 @ASCO Meeting. 📺

0

1

12

Blood Cancers Today

@Blood_Cancers

1 year

🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc

0

5

12

Blood Cancers Today

@Blood_Cancers

3 months

Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with #myelofibrosis . Read more about the study, led by @NicoGagelmann , of @UKEHamburg , and published in @AjHematology . 📰

1

3

12

Blood Cancers Today

@Blood_Cancers

10 months

In this video interview, @GCC_Cortes of @GACancerCenter , reflects on what it meant to receive the Michael J. Keating Award from the @SocietyofHemOnc at #SOHO23 . 📺 #SOHO2023

0

2

12

Blood Cancers Today

@Blood_Cancers

1 year

Jennifer Brown, MD, PhD, Discusses Genomic Evolution of Pirtobrutinib Resistance in Frankfurt at the 2023 EHA Congress @SocietyofHemOnc @EHA_Hematology #EHA2023

1

3

12

Blood Cancers Today

@Blood_Cancers

4 months

🎬 Live in Chicago, it's "The HemOnc Pulse!" 🎉 Get ready for "The HemOnc Pulse" Live on May 3-4 with @chadinabhan as he curates all the latest news in hematology oncology with leaders in the field like @Rfonsi1 , @sanamloghavi , and more! ➡️ Learn more:

0

5

12

Blood Cancers Today

@Blood_Cancers

1 year

ICYMI: @NoopurRajeMD of @MGHCancerCenter / @harvardmed reflects on the mentors who shaped her career, seeing myeloma treatments go from the bench to the bedside, and the importance of personal priorities during a career in academic medicine. 📚:

0

1

12

Blood Cancers Today

@Blood_Cancers

21 days

📈 Achieving complete cytogenetic response results in the longest overall survival in patients with #MDS with abnormal cytogenetics, according to a study presented at #EHA2024 by @SamUrrutia_ of @MDAndersonNews . 📰➡️

0

4

12

Blood Cancers Today

@Blood_Cancers

5 months

Treatment benefit from the FLT3 inhibitor quizartinib was predicted by a “FLT3-like” gene expression signature identified in patients with #AML both with and without FLT3 mutations, according to a study led by @MosqueraOrgeira of @UniversidadeUSC . 📖

0

2

12

Blood Cancers Today

@Blood_Cancers

2 years

While much progress has been made to improve MCL outcomes, there are still many unmet needs. We spoke with Jia Ruan, MD, PhD, of @WeillCornell , @jonathonbcohen , @michaelwangmd , @LymphClinician , and @JainP_MCL , to get their insights. @SocietyofHemOnc

Clinicians Tackle the Challenges of MCL | Blood Cancers Today

Experts discuss areas of progress and where more work is needed to establish a standard of care in mantle cell lymphoma.

www.bloodcancerstoday.com

0

3

12

Blood Cancers Today

@Blood_Cancers

1 year

Is there a link between the microbiome and CAR-T outcomes? Don't miss this video featuring @MarcoRuella of @RuellaLab at @PennMedicine discussing his research on the topic during the 2023 @EHA_Hematology Congress. 📺:

0

4

12

Blood Cancers Today

@Blood_Cancers

7 months

Benjamin Rolles ( @DrRolles ), of @BrighamResearch at @HarvardMed , stopped to chat with Blood Cancers Today at #ASH23 ! Dr. Rolles discussed his abstract on TP53 mutations in patients with MPNs who were treated at @DanaFarber . Check it out ➡️

0

5

9

Blood Cancers Today

@Blood_Cancers

1 month

❔ When should clinicians use fedratinib to treat #myelofibrosis ? A panel with @mpdrc , @doctorpemm , @sanamloghavi , and @myeloidmalig addresses this question. ➡️ Watch here! #HOPLive24 #MPN @AtriumHealthWFB @MDAndersonNews @UChicagoMed

0

3

11

Blood Cancers Today

@Blood_Cancers

1 year

KarMMa-3 results presented by @paurotero of @ClinicaNavarra at @TheEBMT - @EHA_Hematology #CART23 "support use of ide-cel in pts w/early line relapse and triple class-exposed relapsed/refractory multiple myeloma, a pt population with poor survival outcomes."

0

4

11

Blood Cancers Today

@Blood_Cancers

1 year

🔊OUT NOW: In this new episode of The HemOnc Pulse, @graham74GC of @OxfordCancer discusses upfront checkpoint inhibitors in Hodgkin lymphoma, the Holistic Consortium, and more with host @chadinabhan . @SocietyofHemOnc @UniofOxford

0

4

11